Navigation Links
Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams
Date:2/7/2008

CHAPEL HILL, N.C., Feb. 7 /PRNewswire/ -- Selecting and deploying cross- functional, yet sufficiently specialized, brand teams is a new challenge for marketing leaders at pharmas and biotechs. However, best-in-class pharma and biotech firms' brand teams share similar structure, composition, and responsibilities -- all detailed in a new benchmarking report by pharmaceutical research leader Best Practices, LLC.

According to research findings, most brands have a core team of three to 10 people and 86 percent of the pharma and biotech companies reported that the brand team leader sits in the marketing function.

The study, "Best Practices in Designing Effective Brand Teams: Brand Governance and Brand Team Management," yields insights into key benchmarks and strategies for designing effective brand teams. Managers and executives involved with brand teams can use this report to assess their teams and compare structure and governance styles of leading pharmaceutical and biotech brand teams.

A complimentary excerpt of the research report with sample key findings and metrics is reserved for you at http://www3.best-in-class.com/rr908.htm.

The study includes insights gleaned from survey results from brand team managers and executives representing 22 brands in 26 different companies. Deep-dive interviews to flesh out best practices were conducted with 10 managers from the benchmark partners, which included Abbott, Amylin, Bayer, Genentech, GSK, Roche, Novartis and Wyeth.
The comprehensive report reveals findings around key topics, including:

-- Staffing and functional representation for brand teams

-- Brand team operations, decision rights and responsibilities

-- Reporting relationships

-- Performance-based compensation and reviews

-- Brand performance measures

For a detailed report overview and sample metrics, download the report excerpt at http://www3.best-in-class.com/rr908.htm.

For questions or additional information on Best Practices, LLC's other products and services, please call Anna Buhr at 919-809-7560 or email abuhr@best-in-class.com.

If this study is not meeting your current business needs, inquire about starting your own research study or internet survey. Our custom client research will answer your pressing business questions and provide you with actionable insights and process best practices. Please contact Anna Buhr, Manager of Research Operations at abuhr@best-in-class.com to learn more about custom research in HR and other business fields.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
2. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
3. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
4. MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
5. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
6. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
10. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
11. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... Abilene, Texas (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... out to world leaders in hopes of squashing a global crisis with solution to peace ... is guaranteed to work because the plan is given by the Creator Himself. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: